GO:0031397 negative regulation of protein ubiquitination: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031397 (negative regulation of protein ubiquitination) describes any process that stops, prevents, or reduces the addition of ubiquitin groups to a protein.
• It is a biological_process that balances the ubiquitin system and is essential for controlling protein stability, signaling, and degradation.
• Key mechanisms include deubiquitinase activity, competitive inhibition of E3 ligases, and sequestration of ubiquitin-conjugating enzymes.
• Dysregulation of this process is linked to cancer, cardiac hypertrophy, immune disorders, and neurodegeneration.
• Major genes/proteins involved include USP28, CBL, BIRC6, UBA6, HRD1, and ZAP70, among others.
• CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect this pathway.
Description
Protein ubiquitination is a reversible post-translational modification that controls nearly every aspect of eukaryotic cell biology, from protein degradation to signal transduction. The addition of ubiquitin groups to target proteins is orchestrated by a cascade of E1, E2, and E3 enzymes, and its reversal or inhibition is equally important for cellular homeostasis. GO:0031397, negative regulation of protein ubiquitination, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of ubiquitin attachment to a protein. This regulatory layer ensures that ubiquitination events are spatially and temporally controlled, preventing aberrant protein turnover or signaling. For researchers, understanding this process is critical because its dysregulation contributes to a wide range of diseases, including cancer, cardiovascular disorders, and immune pathologies [3,4]. Moreover, the interplay between ubiquitination and deubiquitination is a major focus in drug discovery, as modulating these enzymes can alter disease progression [5,6]. This article provides a comprehensive overview of the ontology, mechanisms, key genes, disease relevance, and experimental strategies for studying negative regulation of protein ubiquitination.
negative regulation of protein ubiquitination At A Glance
| GO ID | GO:0031397 |
|---|---|
| GO term | negative regulation of protein ubiquitination |
| Ontology | biological_process |
| Synonym | down regulation of protein ubiquitination, down-regulation of protein ubiquitination, downregulation of protein ubiquitination, inhibition of protein ubiquitination |
| Major function | Stops, prevents, or reduces the addition of ubiquitin groups to a protein |
| Parent term | negative regulation of protein modification by small protein conjugation or removal |
| Related process | Protein deubiquitination, ubiquitin-dependent protein catabolic process |
| Cellular location | Cytoplasm, nucleus, and organelles where ubiquitination occurs |
What Is GO:0031397?
According to the Gene Ontology, GO:0031397 (negative regulation of protein ubiquitination) is defined as any process that stops, prevents, or reduces the frequency, rate or extent of the addition of ubiquitin groups to a protein. In other words, it is a biological brake on the ubiquitination machinery, ensuring that proteins are not excessively tagged with ubiquitin. This regulation can occur at multiple levels, including inhibition of E1, E2, or E3 enzymes, removal of ubiquitin by deubiquitinases, or sequestration of ubiquitin substrates. The term is a child of 'negative regulation of protein modification by small protein conjugation or removal' and is distinct from positive regulation of ubiquitination.
Why Is negative regulation of protein ubiquitination Important in Cell Biology?
Negative regulation of protein ubiquitination is essential for maintaining proteostasis and preventing inappropriate protein degradation or signaling. It acts as a counterbalance to the ubiquitination machinery, and its disruption can lead to the accumulation of toxic proteins, uncontrolled cell proliferation, or immune dysfunction. For example, the deubiquitinase USP28 negatively regulates antioxidant responses and promotes cardiac hypertrophy by deubiquitinating TRIM21. Similarly, the E3 ligase Cbl family negatively regulates receptor tyrosine kinases, and their dysfunction is implicated in cancers and metabolic disorders. Understanding this process offers therapeutic opportunities, as small molecules or biologics that modulate deubiquitinases or E3 ligases can correct disease-associated imbalances.
• Maintains protein homeostasis by preventing excessive ubiquitination and degradation.
• Regulates immune signaling, including T-cell receptor signaling via ZAP70 ubiquitination.
• Controls cell cycle progression and apoptosis through stabilization of key regulatory proteins.
• Implicated in cancer: circNDUFB2 inhibits non-small cell lung cancer progression by destabilizing IGF2BPs.
• Linked to cardiac hypertrophy via USP28-mediated deubiquitination of TRIM21.
• Modulates stress granule dynamics by inhibiting p62 ubiquitination.
• Affects ER stress and apoptosis through HRD1-induced TMEM2 ubiquitination.
• Plays a role in autophagy regulation via UBA6-BIRC6-mediated ubiquitination of LC3.
• Potential target for therapeutic intervention in neurodegeneration and metabolic diseases.
• Provides a mechanism for fine-tuning receptor tyrosine kinase signaling.
What Happens During negative regulation of protein ubiquitination?
Deubiquitinase-Mediated Removal of Ubiquitin
In simple terms: Enzymes called deubiquitinases cut ubiquitin off target proteins, reversing the tagging process.
Deubiquitinases (DUBs) are proteases that cleave ubiquitin moieties from substrate proteins, directly opposing the action of E3 ligases. This is a major mechanism of negative regulation of protein ubiquitination. For instance, USP28 deubiquitinates TRIM21, thereby stabilizing it and promoting cardiac hypertrophy. Similarly, the NS1 binding protein inhibits p62 ubiquitination, affecting stress granule clearance. DUBs can also regulate immune signaling; for example, ubiquitination of ZAP70 at Lys-217 is negatively regulated, impacting T-cell receptor signaling.
Inhibition of E3 Ligase Activity
In simple terms: Blocking the enzymes that attach ubiquitin prevents proteins from being tagged.
E3 ubiquitin ligases are the specificity factors that recruit ubiquitin-loaded E2 enzymes to substrates. Negative regulation can occur through direct inhibition of E3 ligases, either by binding partners or post-translational modifications. The Cbl family of E3 ligases negatively regulates receptor tyrosine kinases by ubiquitinating them; however, their own activity can be dampened, leading to reduced ubiquitination of RTKs. In rice, strigolactone perception involves regulatory mechanisms that may include inhibition of ubiquitination.
Sequestration of Ubiquitin-Conjugating Enzymes
In simple terms: Hiding the E2 enzymes that carry ubiquitin stops the tagging process.
Some regulatory proteins bind to E2 ubiquitin-conjugating enzymes and prevent them from interacting with E3 ligases, thereby reducing ubiquitination. This mechanism is less characterized but represents a valid point of negative regulation. For example, UBA6 is an E1 enzyme that, in complex with BIRC6, mediates ubiquitination of LC3 to negatively regulate autophagy. While this is a positive ubiquitination event, the pathway illustrates how sequestration or competition can modulate overall ubiquitination flux.
Competitive Substrate Inhibition
In simple terms: A decoy protein mimics the target and soaks up the ubiquitination machinery.
Decoy substrates can compete with genuine targets for E3 ligase binding, reducing the ubiquitination of the latter. This is a form of negative regulation that fine-tunes signaling. For instance, circNDUFB2 acts as a scaffold to destabilize IGF2BPs, indirectly affecting ubiquitination processes in non-small cell lung cancer. Such competitive mechanisms are increasingly recognized in cancer and immune regulation.
Regulation of Ubiquitin Chain Editing
In simple terms: Changing the type of ubiquitin chain can stop degradation signals.
Ubiquitin chains can be edited by DUBs or E3 ligases to alter their topology, converting a degradation signal into a non-degradative one. This is a sophisticated form of negative regulation. HRD1-induced TMEM2 ubiquitination promotes ER stress-mediated apoptosis through a non-canonical pathway, highlighting how chain editing can dictate cell fate. Similarly, the balance between K48- and K63-linked chains is critical in immune signaling.
Key Genes Involved in GO:0031397 negative regulation of protein ubiquitination
The following genes and proteins are central to the negative regulation of protein ubiquitination, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| USP28 | Deubiquitinase that stabilizes TRIM21 | Cardiac hypertrophy, antioxidant response |
| CBL | E3 ligase negatively regulating RTKs | Cancer, metabolic signaling |
| BIRC6 | E3 ligase with UBA6 mediating LC3 ubiquitination | Autophagy regulation |
| UBA6 | E1 enzyme in complex with BIRC6 | Autophagy, ubiquitin activation |
| HRD1 | E3 ligase inducing TMEM2 ubiquitination | ER stress, apoptosis |
| ZAP70 | Kinase ubiquitinated at Lys-217 | T-cell receptor signaling |
| NS1 binding protein | Inhibits p62 ubiquitination | Stress granule dynamics |
| circNDUFB2 | Circular RNA destabilizing IGF2BPs | Non-small cell lung cancer |
| IGF2BP | RNA-binding proteins targeted by circNDUFB2 | Cancer progression |
| TRIM21 | E3 ligase deubiquitinated by USP28 | Cardiac hypertrophy |
| LC3 | Autophagy marker ubiquitinated by UBA6-BIRC6 | Autophagy |
| p62 | Autophagy receptor regulated by ubiquitination | Stress granule clearance |
| TMEM2 | Transmembrane protein ubiquitinated by HRD1 | ER stress apoptosis |
| D14 | Strigolactone receptor in rice | Plant hormone perception |
| MAX2 | F-box protein in strigolactone signaling | Plant development |
| Cbl-b | E3 ligase regulating immune responses | Autoimmunity, cancer |
| Cbl-c | E3 ligase with roles in epithelial cells | Cancer |
How Is negative regulation of protein ubiquitination Regulated?
Negative regulation of protein ubiquitination is itself tightly regulated. Deubiquitinases can be controlled by phosphorylation, ubiquitination, or binding partners. For example, USP28 activity is modulated in cardiomyocytes under stress conditions. E3 ligases like Cbl are regulated by autoubiquitination and interactions with adaptor proteins. Additionally, the availability of ubiquitin and E2 enzymes can influence the overall rate of ubiquitination, and sequestration by proteins like BIRC6 can shift the balance. In plants, strigolactone perception involves regulated ubiquitination of D14 by MAX2, which is a form of negative regulation. These layers of control ensure that ubiquitination is responsive to cellular cues.
negative regulation of protein ubiquitination and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| USP28 | Cardiac hypertrophy | Cardiomyocyte-specific knockout or overexpression in mice |
| CBL | Cancer, metabolic disorders | Cancer cell lines with Cbl mutations or knockout |
| circNDUFB2 | Non-small cell lung cancer | Xenograft models with circNDUFB2 overexpression |
| ZAP70 | Immune disorders | Jurkat T cells with ZAP70 K217R point mutation |
| HRD1 | ER stress, intestinal ischemia/reperfusion | Intestinal epithelial cell knockout models |
Cancer
Dysregulation of negative regulation of protein ubiquitination is frequently observed in cancer. For instance, circNDUFB2 inhibits non-small cell lung cancer progression by destabilizing IGF2BPs and activating anti-tumor immunity. The Cbl family of E3 ligases negatively regulates receptor tyrosine kinases, and loss of Cbl function leads to enhanced RTK signaling and tumorigenesis. Targeting deubiquitinases such as USP28 may offer therapeutic strategies in cancers where these enzymes are overexpressed.
Cardiovascular Disease
Cardiomyocyte-derived USP28 negatively regulates antioxidant response and promotes cardiac hypertrophy via deubiquitinating TRIM21. This highlights how negative regulation of ubiquitination can contribute to heart disease. Modulating USP28 activity could be a potential therapeutic approach for hypertrophy.
Immune Disorders
Negative regulation of TCR signaling by ubiquitination of ZAP70 at Lys-217 is critical for preventing excessive immune activation. Disruption of this process can lead to autoimmunity or immunodeficiency. Additionally, NS1 binding protein regulates stress granule dynamics by inhibiting p62 ubiquitination, which may impact antiviral responses.
Neurodegeneration and ER Stress
HRD1-induced TMEM2 ubiquitination promotes ER stress-mediated apoptosis through a non-canonical pathway in intestinal ischemia/reperfusion. This suggests that negative regulation of ubiquitination is important in stress responses and may be relevant to neurodegenerative diseases where ER stress is a hallmark.
From negative regulation of protein ubiquitination-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of USP28 affect cardiac hypertrophy? | USP28 knockout mice or cardiomyocyte-specific KO |
| How does Cbl mutation affect RTK signaling? | Cbl knockout cell lines or point mutants |
| What is the role of ZAP70 K217 ubiquitination in TCR signaling? | ZAP70 K217R knock-in mice or Jurkat cells |
| Can circNDUFB2 overexpression suppress lung cancer? | Lung cancer xenografts with circNDUFB2 overexpression |
| Does HRD1-mediated TMEM2 ubiquitination promote apoptosis? | HRD1 knockout intestinal epithelial cells |
| How does NS1 binding protein regulate stress granules? | NS1 BP knockout or overexpression in stress granule models |
How to Study the negative regulation of protein ubiquitination Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro ubiquitination assay | Rate of ubiquitin conjugation | Testing direct inhibition by DUBs or inhibitors |
| Mass spectrometry | Ubiquitination sites and abundance | Mapping sites on ZAP70, TMEM2 |
| CRISPR knockout screen | Genes affecting ubiquitination | Identifying negative regulators in cancer |
| RNA-seq | Transcriptional changes | Assessing downstream effects of USP28 modulation |
| Western blot | Protein stability and ubiquitination levels | Validating candidate regulators |
| Immunoprecipitation | Protein-protein interactions | Detecting E3-substrate complexes |
| Live-cell imaging | Real-time ubiquitination dynamics | Studying stress granule clearance |
| Flow cytometry | Cell surface receptor levels | Measuring RTK ubiquitination and degradation |
Ubiquitination Assays
In vitro ubiquitination assays using recombinant E1, E2, E3, and substrate proteins can measure the rate of ubiquitin conjugation. These assays are essential to dissect the direct effects of negative regulators. For example, the UBA6-BIRC6 complex was shown to ubiquitinate LC3 in vitro. Similarly, HRD1-mediated TMEM2 ubiquitination was demonstrated using such assays.
Proteomics and Mass Spectrometry
Mass spectrometry-based proteomics can identify ubiquitination sites and quantify changes in ubiquitination status upon modulation of negative regulators. This approach has been used to map ZAP70 ubiquitination at Lys-217 and to study global ubiquitination changes in cancer cells.
CRISPR Screens
Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate protein ubiquitination. For instance, screens targeting deubiquitinases or E3 ligases can reveal modifiers of a specific substrate's stability. This is particularly useful for discovering novel regulators in diseases like cancer.
Imaging and Live-Cell Tracking
Fluorescently tagged ubiquitin or substrates can be used to monitor ubiquitination dynamics in live cells. This method has been applied to study stress granule dynamics regulated by p62 ubiquitination and to visualize LC3 ubiquitination in autophagy.
How CRISPR Can Be Used to Study GO:0031397 negative regulation of protein ubiquitination
Knockout
CRISPR knockout of genes encoding negative regulators of ubiquitination, such as USP28 or Cbl, can reveal their physiological roles. For example, USP28 knockout in cardiomyocytes would test its role in hypertrophy. Knockout of Cbl family members can lead to enhanced RTK signaling and cancer progression.
Point Mutation
Introducing point mutations in ubiquitination sites, such as ZAP70 K217R, can prevent ubiquitination and assess its functional impact on TCR signaling. Similarly, mutations in DUB catalytic domains can abolish their activity and clarify their contribution to negative regulation.
Knock-in
Knock-in of tagged ubiquitin or substrate proteins allows for tracking and purification. For instance, knocking in a fluorescent tag on LC3 can monitor its ubiquitination by UBA6-BIRC6 in autophagy. Knock-in of disease-associated mutations can model human disorders.
Overexpression
Overexpression of negative regulators like circNDUFB2 can suppress cancer progression by destabilizing oncoproteins. Overexpressing DUBs such as USP28 can promote hypertrophy, providing a gain-of-function model.
How EDITGENE Supports negative regulation of protein ubiquitination Research
Researchers studying negative regulation of protein ubiquitination-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. This requires precise genetic manipulation to avoid confounding effects from compensatory pathways.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of protein ubiquitination research.
Frequently Asked Questions About negative regulation of protein ubiquitination
What is GO:0031397?
GO:0031397 is the Gene Ontology term for negative regulation of protein ubiquitination, defined as any process that stops, prevents, or reduces the addition of ubiquitin groups to a protein.
What genes are involved in negative regulation of protein ubiquitination?
Key genes include USP28, CBL, BIRC6, UBA6, HRD1, ZAP70, and circNDUFB2, among others [1,3,4,5,6,7].
How does negative regulation of ubiquitination affect cancer?
It can suppress tumor progression; for example, circNDUFB2 inhibits non-small cell lung cancer by destabilizing IGF2BPs. Loss of Cbl E3 ligases leads to enhanced RTK signaling and cancer.
What diseases are linked to dysregulated protein ubiquitination?
Cancer, cardiac hypertrophy, immune disorders, and ER stress-related conditions are linked to dysregulation of this process [3,4,5,6,7].
What are the mechanisms of negative regulation of protein ubiquitination?
Mechanisms include deubiquitinase activity, inhibition of E3 ligases, sequestration of E2 enzymes, and competitive substrate inhibition [1,3,4,7].
How can I study negative regulation of protein ubiquitination using CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of genes like USP28, CBL, and ZAP70 [3,4,7].
What is the role of USP28 in cardiac hypertrophy?
USP28 deubiquitinates TRIM21, stabilizing it and promoting cardiac hypertrophy.
How does ZAP70 ubiquitination regulate T-cell signaling?
Ubiquitination of ZAP70 at Lys-217 negatively regulates TCR signaling, and preventing this ubiquitination alters immune responses.
What is the connection between ubiquitination and autophagy?
UBA6-BIRC6-mediated ubiquitination of LC3 negatively regulates autophagy.
What experimental models are best for studying negative regulation of ubiquitination?
Knockout mice, point mutant cell lines, and overexpression xenografts are commonly used, depending on the gene and disease context [3,4,5,7].
Conclusion
Negative regulation of protein ubiquitination (GO:0031397) is a fundamental biological process that counterbalances the ubiquitin system to maintain cellular homeostasis. Its dysregulation is implicated in cancer, cardiovascular disease, immune disorders, and stress responses. Key regulators such as USP28, CBL, and ZAP70 provide promising targets for therapeutic intervention. Advances in CRISPR-based models and proteomic technologies continue to unravel the complexities of this process, offering new opportunities for drug discovery and precision medicine.
References
- 1. Jia R et al.. 2019. Negative regulation of autophagy by UBA6-BIRC6-mediated ubiquitination of LC3.. Elife 8 PMID: 31692446
- 2. Hu Q et al.. 2024. Regulatory mechanisms of strigolactone perception in rice.. Cell 187(26):7551-7567.e17 PMID: 39500324
- 3. Han J et al.. 2024. Cardiomyocyte-derived USP28 negatively regulates antioxidant response and promotes cardiac hypertrophy via deubiquitinating TRIM21.. Theranostics 14(16):6236-6248 PMID: 39431010
- 4. Tang R et al.. 2022. Negative regulation of receptor tyrosine kinases by ubiquitination: Key roles of the Cbl family of E3 ubiquitin ligases.. Front Endocrinol (Lausanne) 13:971162 PMID: 35966060
- 5. Li B et al.. 2021. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity.. Nat Commun 12(1):295 PMID: 33436560
- 6. Zhao X et al.. 2024. HRD1-induced TMEM2 ubiquitination promotes ER stress-mediated apoptosis through a non-canonical pathway in intestinal ischemia/reperfusion.. Cell Death Dis 15(2):154 PMID: 38378757
- 7. Ivanova E et al.. 2016. Negative regulation of TCR signaling by ubiquitination of Zap-70 Lys-217.. Mol Immunol 73:19-28 PMID: 27032069
- 8. Jeon P et al.. 2024. NS1 binding protein regulates stress granule dynamics and clearance by inhibiting p62 ubiquitination.. Nat Commun 15(1):10925 PMID: 39738171
